APOL1 and kidney disorder: In conclusion, CRISPR-based genotyping may help making accurate diagnosis of APOL1-mediated kidney disease widely accessible due to its increased speed and cost-effectiveness as compared to Sanger sequencing, thereby enabling early preventative measures and monitoring of disease (Appendix Table S3).